Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $104.8 million.

  • Orchestra BioMed Holdings' Liabilities and Shareholders Equity rose 3915.08% to $104.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.9 million, marking a year-over-year decrease of 1311.23%. This contributed to the annual value of $76.2 million for FY2024, which is 1999.64% down from last year.
  • As of Q3 2025, Orchestra BioMed Holdings' Liabilities and Shareholders Equity stood at $104.8 million, which was up 3915.08% from $42.8 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' Liabilities and Shareholders Equity's 5-year high stood at $161.6 million during Q2 2022, with a 5-year trough of $42.8 million in Q2 2025.
  • Its 4-year average for Liabilities and Shareholders Equity is $98.3 million, with a median of $95.2 million in 2023.
  • In the last 5 years, Orchestra BioMed Holdings' Liabilities and Shareholders Equity skyrocketed by 6949.54% in 2023 and then tumbled by 4249.98% in 2024.
  • Quarter analysis of 4 years shows Orchestra BioMed Holdings' Liabilities and Shareholders Equity stood at $95.6 million in 2022, then decreased by 0.38% to $95.2 million in 2023, then decreased by 20.0% to $76.2 million in 2024, then soared by 37.59% to $104.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $104.8 million in Q3 2025, compared to $42.8 million in Q2 2025 and $59.1 million in Q1 2025.